Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
PARSIPPANY, N.J., Feb. 15, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Pacira Pharmaceuticals management team is scheduled to participate in an analyst-led fireside chat at the 2017 RBC Capital Markets’ Healthcare Conference at 10:00 a.m. ET on Wednesday, February 22, 2017, in New York.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco, (973) 451-4030 [email protected]
